Nonselective beta-adrenoceptor blocker use and risk of Parkinson's disease: from multiple real-world evidence

被引:5
作者
Feng, Zeying [1 ,2 ]
Zhao, Qiuping [3 ]
Wu, Jingjing [2 ]
Yang, Yiping [2 ]
Jia, Xinru [2 ]
Ma, Junlong [2 ]
Tang, Haibo [4 ]
Yuan, Hong [2 ]
Yang, Guoping [2 ,5 ]
Lu, Yao [2 ,6 ]
机构
[1] Liuzhou Hosp, Clin Trial Inst Off, Guangzhou Women & Childrens Med Ctr, Liuzhou, Peoples R China
[2] Cent South Univ, Xiangya Hosp 3, Clin Res Ctr, 138 TongZiPo Rd, Changsha 410013, Hunan, Peoples R China
[3] Fuwai Cent China Cardiovasc Hosp, Henan Prov Peoples Hosp, Heart Ctr, Zhengzhou, Peoples R China
[4] Cent South Univ, Xiangya Hosp 3, Dept Metab & Bariatr Surg, Changsha, Peoples R China
[5] Cent South Univ, XiangYa Sch Pharmaceut Sci, Changsha, Peoples R China
[6] Kings Coll London, Sch Life Course Sci, London, England
关键词
Antihypertensive agents; Parkinson's disease; UK Biobank; Real-world study; CALCIUM-CHANNEL BLOCKERS;
D O I
10.1186/s12916-023-03122-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundPeople with hypertension have a higher risk of developing Parkinson's disease (PD), epidemiological evidence suggests that multiple antihypertensives may affect the occurrence and development of PD with inconsistent results. With multisource data, we sought to determine whether specific antihypertensive classes elevated or reduced the risk for PD.MethodsWe used a mixed methods approach that combines 4 methodologies. First, we conducted a disproportionality analysis using the reports causing adverse events in the US Food and Drug Administration Adverse Events Reporting System (FAERS) to explore the effect of different classes of antihypertensive medications on the risk of PD; based on the findings from FAERS, a meta-analysis and a UK Biobank cohort analysis were used to further assess the association of drug use with PD; finally, we employed Mendelian randomization (MR) analysis to validate the causal relationship between the drug target and the occurrence of PD.ResultsIn the disproportionality analysis using the FAERS (N = 187,266), nonselective beta-adrenoceptor blockers (NBBs) were demonstrated to have a significant association with PD (reporting odds ratio (ROR) = 3.13; 95% CI 2.33-4.22). In the meta-analysis of 12 studies with 12,183,809 participants, PD risk was elevated in NBBs (RR, 1.64; 95% CI, 1.19-2.09) when stratified by subtypes of BBs. Among the 105,763 participants included in the cohort analysis using data from the UK Biobank, individuals who used NBBs had a significantly increased risk of PD compared to nonusers (HR, 1.47; 95% CI 1.04-2.06). The MR analysis revealed a significant association between higher expression of the beta 2 adrenergic receptor (ADRB2) gene, a drug target blocked by NBBs, and a reduced risk of PD (OR, 0.85; 95% CI 0.73-0.99).ConclusionsOur comprehensive study indicated that regular NBB use is associated with an increased risk of PD. In light of the detrimental effects of NBBs on PD, some people should choose alternative antihypertensive treatments.
引用
收藏
页数:10
相关论文
共 30 条
  • [1] Atkins D, 2004, BMJ-BRIT MED J, V328, P1490
  • [2] Use of antihypertensives and the risk of Parkinson disease
    Becker, Claudia
    Jick, Susan S.
    Meier, Christoph R.
    [J]. NEUROLOGY, 2008, 70 (16) : 1438 - 1444
  • [3] Parkinson's disease
    Bloem, Bastiaan R.
    Okun, Michael S.
    Klein, Christine
    [J]. LANCET, 2021, 397 (10291) : 2284 - 2303
  • [4] Pharmacovigilance-based drug repurposing: The search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections
    Boehm, Ruwen
    Bulin, Claudia
    Waetzig, Vicki
    Cascorbi, Ingolf
    Klein, Hans-Joachim
    Herdegen, Thomas
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (11) : 4421 - 4431
  • [5] Comprehensive Real-World Assessment of Marketed Medications to Guide Parkinson's Drug Discovery
    Cepeda, M. Soledad
    Kern, David M.
    Seabrook, Guy R.
    Lovestone, Simon
    [J]. CLINICAL DRUG INVESTIGATION, 2019, 39 (11) : 1067 - 1075
  • [6] Association between Hypertension and the Risk of Parkinson's Disease: A Meta-Analysis of Analytical Studies
    Chen, Jiahao
    Zhang, Caixia
    Wu, Yanjun
    Zhang, Dongfeng
    [J]. NEUROEPIDEMIOLOGY, 2019, 52 (3-4) : 181 - 192
  • [7] Clinical Progression in Parkinson Disease and the Neurobiology of Axons
    Cheng, Hsiao-Chun
    Ulane, Christina M.
    Burke, Robert E.
    [J]. ANNALS OF NEUROLOGY, 2010, 67 (06) : 715 - 725
  • [8] β-Adrenoceptor Drugs and Parkinson's Disease: A Nationwide Nested Case-Control Study
    de Germay, Sibylle
    Conte, Cecile
    Rascol, Olivier
    Montastruc, Jean-Louis
    Lapeyre-Mestre, Maryse
    [J]. CNS DRUGS, 2020, 34 (07) : 763 - 772
  • [9] Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports
    Evans, SJW
    Waller, PC
    Davis, S
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2001, 10 (06) : 483 - 486
  • [10] β2-Agonists and the Incidence of Parkinson Disease
    Giorgianni, Francesco
    Ernst, Pierre
    Dell'Aniello, Sophie
    Suissa, Samy
    Renoux, Christel
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2020, 189 (08) : 801 - 810